Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right
For almost half a century, cardiac transplant has been the only long-term treatment for patients with end-stage heart failure. Implantable left ventricular assist devices (LVADs) have emerged as a new treatment option for advanced heart failure as destination therapy for patients either too old or n...
Guardado en:
Autores principales: | Antoni Bayes-Genis, Christian Muñoz-Guijosa, Evelyn Santiago-Vacas, Santiago Montero, Cosme García-García, Pau Codina, Julio Núñez, Josep Lupón |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Radcliffe Medical Media
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/be4155e7d29f46fea89718127ee72f06 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence
por: Antoni Bayes-Genis, et al.
Publicado: (2021) -
Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018
por: Giosafat Spitaleri, et al.
Publicado: (2021) -
Prominent differences in left ventricular performance and myocardial properties between right ventricular and left ventricular-based pacing modes in rats
por: Wesam Mulla, et al.
Publicado: (2017) -
Limited value of cystatin-C over estimated glomerular filtration rate for heart failure risk stratification.
por: Elisabet Zamora, et al.
Publicado: (2012) -
Development of a novel heart failure risk tool: the barcelona bio-heart failure risk calculator (BCN bio-HF calculator).
por: Josep Lupón, et al.
Publicado: (2014)